HERON THERAPEUTICS INC

Heron Therapeutics COO Mark Earl’s buy‑sell‑buy trade signals strong insider confidence and rising social‑media buzz, hinting at a near‑term rebound for the biotech stock.

Heron Therapeutics insider buying signals confidence ahead of FDA review—discover why William P. Forbes’ July 30 trade may be a bullish entry point.

Heron Therapeutics insider buying reveals CFO Duarte Ira’s confidence in its biochronomer platform—watch how strategic purchases may spark a rebound.

Heron Therapeutics CEO Craig Collard ramps up insider buying—RSU grants and stock purchases—signaling confidence in the biotech’s drug‑delivery platform and hinting at future upside for investors.

Heron Therapeutics insider activity: Duarte Ira’s recent 12,500‑share buy shows contrarian optimism amid a steep 80% YTD drop, but investors must weigh weak fundamentals, pending regulatory milestones and competitive risks before trusting insider co…

Heron Therapeutics insider buying signals optimism: CEO’s fresh 3,874‑share purchase boosts confidence, sparks a 14% weekly rally and 34% monthly gain, highlighting potential gains from biochronomer tech and partnership deals.

Heron Therapeutics insider trading: CEO Collard’s 13,797‑share buy after selling RSUs signals confidence in short‑term prospects and a strategic shift ahead of new equity plans.

Heron Therapeutics insider buys reveal confidence in its biochronomer platform, fast‑track reformulations, and strong early‑stage clinical gains.

Heron Therapeutics insider buying signals potential upside amid negative earnings – explore how exec trades may hint at undervalued biotech stock.